27 results on '"Chang, Daniel Tandel"'
Search Results
2. Clinical determinants of survival in patients with stage II-III pancreatic cancer.
3. Predicting rapid progression and overall survival in stage II-III pancreatic cancer using a CT-based radiomic signature.
4. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms
5. Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer.
6. Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX).
7. Type of fiducial marker and clinical outcomes in stereotactic body radiation therapy for pancreatic cancer.
8. Clinical outcomes of hepatocellular carcinoma patients with Child-Pugh class B treated with stereotactic body radiation therapy.
9. Emergency department use at the end of life in elderly patients with gastrointestinal malignancies and mental health comorbidities.
10. Risk of subsequent cancer diagnosis in patients treated with 3D conformal, intensity modulated, or proton beam radiation therapy.
11. Downstaging and survival after neoadjuvant approaches to gastroesophageal junction adenocarcinoma.
12. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at a single institution.
13. Microsatellite instability and adjuvant chemotherapy in stage II colon cancer.
14. Can looking at density differences between liver parenchyma and oligometastatic lesions predict outcomes and toxicities in patients receiving stereotactic body radiation therapy for metastatectomy?
15. Prediction of pancreatic cancer surgical outcomes and prognosis based on an objective resectability scoring system.
16. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
17. Socioeconomic resources and survival in patients with metastatic breast cancer treated with palliative radiotherapy.
18. Fractionation of palliative radiotherapy in metastatic breast cancer: Selection and survival.
19. Survival comparison of patients treated with one versus five fraction palliative radiotherapy.
20. Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.
21. A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.
22. A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.
23. Pre-SBRT metabolic tumor volume and total lesion glycolysis to predict survival in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
24. Effects of gemcitabine and stereotactic body radiotherapy on quality of life in locally advanced pancreatic cancer.
25. Clinical deployment of automatic treatment planning for pancreas SBRT patients.
26. Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.
27. A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.